Pharmacology and prescribing in hypertension by Robertson, DAF
Pharmacology and prescribing in 
hypertension
Robertson, DAF
10.12968/npre.2018.16.10.497
Title Pharmacology and prescribing in hypertension
Authors Robertson, DAF
Type Article
URL This version is available at: http://usir.salford.ac.uk/id/eprint/48785/
Published Date 2018
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
Pharmacology and Prescribing in Hypertension 
Abstract 
In this article in the series of ‘bite sized’ pharmacology, we will look at the pharmacological 
actions of drugs used in the management of hypertension. This article will outline the issues 
and areas of intervention required in hypertension with reference to current guidelines and 
formulary.  It will illustrate the common therapeutic interventions in patients with Stage 1, 
Stage 2 and Severe Hypertension taking into account a stepwise approach incorporating inter 
individual variations affecting drug choice. 
It will then go on to examine the main types of drug used and their pharmacodynamic 
actions. The management will be considered within the NICE guidance and evidence base.  
Exercises will be provided to help you apply this knowledge to your prescribing practice.  
 
Hypertension 
 Free stock photo Pixabay 
Hypertension can be broken down into two distinct categories; 
Essential hypertension- This is where there is no direct attributable cause to explain the 
persistently elevated blood pressure. 
Secondary hypertension- This is where the raised blood pressure can be attributed, wholly or 
partly to another primary condition  
• Diabetes 
• Renal Disease 
• Thyroid Disease 
• Cushings Syndrome- steroids used to treat 
• Pheochromocytoma 
• Obesity 
• Pregnancy 
The National Institute for Health & Care Excellence have produced guidelines for the 
diagnosis and management of hypertension in adults (NICE CG127- 
https://www.nice.org.uk/guidance/cg127 ). 
It defines hypertension in the following way 
• Stage 1 hypertension Clinic blood pressure is 140/90 mmHg or 
higher and subsequent ambulatory blood pressure monitoring (ABPM) daytime 
average or home blood pressure monitoring (HBPM) average blood pressure is 
135/85 mmHg or higher. 
• Stage 2 hypertension Clinic blood pressure is 160/100 mmHg or 
higher and subsequent ABPM daytime average or HBPM average blood pressure is 
150/95 mmHg or higher. 
• Severe hypertension Clinic systolic blood pressure is 180 mmHg or higher or clinic 
diastolic blood pressure is 110 mmHg or higher. 
Exercise 
With reference to your own area of practice, explore the categories of hypertensive patients 
you deal with and establish the diagnosis of the condition within recognised guidelines and 
parameters. 
 
The primary goal of drug therapy is to improve cardiovascular function and reduce the 
clinical symptoms as well as preventing secondary conditions or major events. 
 Table 1: Drugs Commonly Used in the Management of Hypertension 
Action of Drug  Class Examples 
Cardio-inhibitory Beta-adrenoceptor Blockers 
Calcium Channel Blockers 
Vasodilators Angiotensin Converting Enzyme 
Inhibitors 
Angiotensin receptor Blockers 
Diuretics Thiazide Diuretics 
Loop Diuretics 
Potassium Sparing Diuretics 
 
Exercise 
Using pharmacologically available resources such as textbooks, the BNF or online electronic 
medicines compendium, explore the range of anti-hypertensive drugs available.  
Reconcile this with your local policy on prescribing in hypertension and NICE Guidance. 
 
Pharmacology of Individual Classes of Drugs         
Diuretics 
Diuretic drugs increase urine output by the kidney (i.e. promote diuresis). This is 
accomplished by altering how the kidney handles sodium and water (Rang et al 2015). If the 
kidney excretes more sodium, then water excretion will also increase. Most diuretics produce 
diuresis by inhibiting the reabsorption of sodium at different segments of the renal tubular 
system (see figure 1). Sometimes a combination of two diuretics is given because this can be 
significantly more effective than either compound alone (synergistic effect). 
   
Figure 1- The renal Tubular System from Wikimedia Commons 
 
Loop diuretics have their effect by a profound inhibition of the sodium-potassium-chloride 
co-transporter located in the thicker ascending portion of the loop part of the nephron. This 
efficient transporter is responsible for 25% of the sodium reabsorption that occurs. Blockade 
of this normal mechanism gives rise to an increase in the concentration of sodium found in 
the distal tubule, and as a result there is less water reabsorption into the collecting duct, as the 
water stays with the higher sodium level. This promotes diuresis (water excretion) and 
natriuresis (sodium excretion). Loop diuretics are very strong diuretics (Neal 2016). These 
drugs also promote production of prostaglandins by the kidney itself. These are needed to 
maintain normal kidney function and increase the efficacy of these drugs by contributing to 
renal blood flow efficiency.  
They are useful if added to other antihypertensive treatment to improve control in those with 
resistant hypertension or impaired renal function (BNF2018).  
 
Examples- furosemide and bumetanide. 
Thiazide and related diuretics, have their action by inhibition of the sodium-chloride 
transporter mechanism found in the distal tubule of the nephron. This system is responsible 
for around 5% reabsorption of sodium, meaning that these drugs are classed as weaker than 
loop diuretics (Barber and Robertson 2015).  
They are however often adequately strong enough to produce the necessary diuretic effect.  
 
Examples- Bendroflumethiazide, Indapamide. 
 
Potassium sparing diuretics, antagonize the actions of aldosterone in the distal part of the 
distal tubule. This allows more sodium and the water that naturally follows, to move to the 
collecting duct for excretion in the urine. They do not produce hypokalaemia to the same 
extent as the loop and thiazide diuretics. This is because inhibition of aldosterone-sensitive 
sodium reabsorption, means that there is a reduction in the amount of potassium and 
hydrogen exchanged for sodium by this transport mechanism.   
Other diuretics in this class can have their effects by directly inhibiting sodium channels 
collocated with the aldosterone-sensitive sodium pump, and have similar effects (Neal 2016).  
This class of diuretic is categorised as a weak diuretic, and as such they are often used in 
combination with thiazide or loop diuretics to reduce the potential hypokalaemia associated 
with those drugs (BNF 2018).  
Examples – Amiloride, Spironolactone 
 
 
 
Vasodilators 
As the name implies, vasodilator drugs relax the smooth muscle in blood vessels, which 
causes the vessels to dilate. Dilation of arterial (resistance) vessels leads to a reduction in 
systemic vascular resistance, which leads to a fall in arterial blood pressure. Dilation of 
venous (capacitance) vessels decreases venous blood pressure.  
The Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers 
(ARB’s) are examples of vasodilatory drugs used in hypertension. There actions are on the 
Renin-Angiotensin-Aldosterone System (see figure 2) where vasoconstriction is part of the 
normal mechanism. 
 
Figure 2 Renin-Angiotensin-Aldosterone System from Wikimedia Commons 
  
ACE inhibitors  
These cause vasodilation by blocking angiotensin II production and inhibiting the metabolism 
of bradykinin. This in turn reduces arterial pressure, and the work of the heart.  
They also reduce sympathetic activity produced by adrenaline by blocking the effects of 
angiotensin II on sympathetic nerve modulation of noradrenaline. This blocks the normal 
vasoconstrictive mechanisms.  
In addition they promote the excretion of sodium and water by the kidney through a process 
where the action of angiotensin II in the kidney is inhibited as is aldosterone secretion. This 
reduces circulating volume, and in turn reduces blood pressure.  
Examples- Enalapril, Ramapril, Perindopril 
 
ARBs  
These drugs are receptor antagonists that block angiotensin II receptors on blood vessels and 
in the heart. These receptors stimulate vascular smooth muscle contraction. Blocking this 
contraction produces relaxation and dilation. They do not inhibit ACE, and therefore do not 
increase bradykinin metabolism, which contributes to the side effects of ACE inhibitors such 
as persistent dry cough and angioedema.  
Examples- Candesartan, Irbesartan 
 
Cardio Inhibitory Drugs 
Beta Adrenoceptor Blockers 
Beta-blockers are drugs that bind to beta-adrenoceptors and thereby block the binding of 
noradrenaline and adrenaline to these receptors. This inhibits normal sympathetic effects that 
act through these g-protein coupled receptors. These g protein receptors are linked to cyclic 
adenosine monophosphate (cAMP). The heart contains β1 and β2 subtypes, but β1 
outnumbers β2. The smooth muscle of the rest of the vascular system has β2-adrenoceptors. 
Beta blockers have relatively little vascular effects and the majority effect is produced 
through cardiac modulation. They lead to a reduction in cardiac output and can decrease heart 
rate and may have an effect on renin production form the kidney. An additional effect is 
altered baroreceptor reflex sensitivity which is a parasympathetic activity (BNF 2018). 
Examples- Propranolol, Bisoprolol, Metoprolol. 
Calcium Channel Blockers (CCBs) 
Many CCBs bind to L-type calcium channels which are found in vascular smooth muscle. 
The channels regulate the movement of calcium ions into muscle cells. This movement is the 
precursor to smooth muscle contraction. The inhibition of this normal mechanism causes 
vascular smooth muscle relaxation. The dihydropyridine class of CCBs is commonly used as 
they have a high affinity for vascular tissue. Non-dihydropyridine drugs have a relatively 
high affinity but are not as selective as the dihydropyridine class. 
Examples- Amlodipine (dihydropyridine), Diltiazem, Verapamil (non-dihydropyridine). 
 
Exercise 
Using pharmacologically available resources such as textbooks, the BNF or online electronic 
medicines compendium, look up the specific class and modes of action of drugs you regularly 
expect to prescribe. Use this information to augment your personal formulary knowledge. 
 
Stock Photo 
NICE Guidelines give a good overview of which antihypertensive is most appropriate 
depending on the stage of hypertension and the individual characteristics of the patient, 
including age, sex and family origin, but it is important that we consider how to apply the 
guidelines within the context of the actual patient in front of us and ensure that we do not 
blindly and rigorously apply the guidelines, but rather use them to tailor a patient specific 
plan for the people we are prescribing for.   
 
Reflective Exercise 
Access the NICE guidance and choose, for a typical patient from your area of practice, the 
most appropriate first line treatment based on evidence. 
(https://www.nice.org.uk/guidance/cg127) 
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